TY - JOUR
T1 - Talking about recommended age or fewer doses
T2 - what motivates HPV vaccination timeliness?
AU - Margolis, Marjorie A.
AU - Brewer, Noel T.
AU - Shah, Parth D.
AU - Calo, William A.
AU - Alton Dailey, Susan
AU - Gilkey, Melissa B.
N1 - Funding Information:
Brewer has served on paid advisory boards and/or received research grants from Merck, Pfizer and GSK.
Funding Information:
This study was funded by the Centers for Disease Control and Prevention (CDC) [PI Brewer: grant #3U48DP005017-03S6]. Margolis’ time was supported by National Cancer Institute award [T32 CA057726]. Funders played no role in: 1) study design; 2) the collection, analysis, and interpretation of data; 3) the writing of the report; or 4) the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of CDC or NCI.
Publisher Copyright:
© 2021 Taylor & Francis Group, LLC.
PY - 2021
Y1 - 2021
N2 - HPV vaccination is recommended for U.S. adolescents at ages 11–12 and requires two versus three doses if the series is started before age 15. We evaluated how talking about recommended age or fewer doses motivates on-time HPV vaccination. Our national, online experiment randomized 1,263 parents of adolescents to view one of three messages about HPV vaccination recommendations or no message. Messages framed guidelines as recommending: vaccination at age 11–12; fewer doses for those who start vaccination at age 11–12; or, fewer doses for those who start vaccination before age 15. We then assessed parents’ preferred age for HPV vaccination, categorizing preferences of ≤12 years as on-time. Parents who viewed “at age 11–12” versus no message more often preferred on-time HPV vaccination (63% vs. 43%, p < .05) and did not differ from those viewing “fewer doses at age 11–12” (63% vs. 64%, p > .05). Parents who viewed “fewer doses before age 15” less often preferred on-time HPV vaccination (39%, p < .05). Recommending HPV vaccination at age 11–12 encouraged on-time vaccination, while offering fewer doses had little impact. Providers should avoid framing HPV vaccination guidelines in reference to age 15 because doing so may discourage on-time vaccination by introducing confusion about the recommended age.
AB - HPV vaccination is recommended for U.S. adolescents at ages 11–12 and requires two versus three doses if the series is started before age 15. We evaluated how talking about recommended age or fewer doses motivates on-time HPV vaccination. Our national, online experiment randomized 1,263 parents of adolescents to view one of three messages about HPV vaccination recommendations or no message. Messages framed guidelines as recommending: vaccination at age 11–12; fewer doses for those who start vaccination at age 11–12; or, fewer doses for those who start vaccination before age 15. We then assessed parents’ preferred age for HPV vaccination, categorizing preferences of ≤12 years as on-time. Parents who viewed “at age 11–12” versus no message more often preferred on-time HPV vaccination (63% vs. 43%, p < .05) and did not differ from those viewing “fewer doses at age 11–12” (63% vs. 64%, p > .05). Parents who viewed “fewer doses before age 15” less often preferred on-time HPV vaccination (39%, p < .05). Recommending HPV vaccination at age 11–12 encouraged on-time vaccination, while offering fewer doses had little impact. Providers should avoid framing HPV vaccination guidelines in reference to age 15 because doing so may discourage on-time vaccination by introducing confusion about the recommended age.
UR - http://www.scopus.com/inward/record.url?scp=85105860530&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105860530&partnerID=8YFLogxK
U2 - 10.1080/21645515.2021.1912550
DO - 10.1080/21645515.2021.1912550
M3 - Article
C2 - 33961539
AN - SCOPUS:85105860530
SN - 2164-5515
VL - 17
SP - 3077
EP - 3080
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
IS - 9
ER -